Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00192660
Status:
COMPLETED
Last Update Posted:
2012-04-12
First Post:
2005-09-12
Brief Title:
HIV Infection And Metabolic Abnormalities Protocol 1 HAMA001
Sponsor:
Kirby Institute
Organization:
Kirby Institute
Study Overview
Official Title:
Analysis of Lipodystrophy in HIV-Infected Individuals A Prospective Non-randomised 48 Week Study of the Effect of PI Containing and Non-PI Containing Antiretroviral Regimens on the Expression of Adipocyte Specific Genes Protein Levels and Cellular Structure in HIV-infected Individuals Naive to Therapy Who Are Starting Therapy for the First Time
Status:
COMPLETED
Status Verified Date:
2012-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective non-randomised 48 week study of the effect of protease inhibitor PI containing and non-PI containing antiretroviral regimens on the expression of adipocyte specific genes protein levels and cellular structure in HIV-infected individuals naive to therapy who are starting therapy for the first time
Detailed Description:
Antiretroviral medications used to treat HIV infection cause side effects These include changes in composition of fat throughout the body loss in some areas and accumulation in others elevations in blood lipids and abnormalities in glucose metabolism The resulting syndrome is known as HIV associated lipodystrophy or HIVLD In HIV negative populations such abnormalities in lipid and glucose metabolism are associated with an increased risk of developing cardiovascular disease CVD The aim of this study is to characterize the changes that occur in body composition and metabolism with antiretroviral treatment and compare them to changes in fat tissue structure and function and surrogate markers for cardiovascular disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01HL065953-01 | NIH | None | httpsreporternihgovquickSearchR01HL065953-01 |